Industry / United States
CRO Sector Benefiting From Boom
January 2008 | Industry NewsIncreased regulatory scrutiny from the US FDA is resulting in the rapid growth of contract research organisations (CROs) in the US, with the share prices of some of the major players tripling over the past five years. With more and more drugmakers conducting post-marketing studies,
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
